Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers' perspectives.
Evgenia GourgariLina Huerta-SaenzKsenia N TonyushkinaElizabeth T RosolowskyInes Guttmann-BaumanPublished in: Pediatric diabetes (2021)
The use of GLP-1RA has increased in pediatric patients. Recent Food and Drug Administration approval of liraglutide for pediatric obesity will likely further increase its prescription rate. Providers should be vigilant about side effects and adjust the doses of GLP-1RA accordingly. More efforts should be made by professional societies to educate pediatric endocrinology providers about the proper use of GLP-1RA and enhance their confidence in prescribing these medications.
Keyphrases
- drug administration
- type diabetes
- rheumatoid arthritis
- insulin resistance
- metabolic syndrome
- weight loss
- disease activity
- high fat diet induced
- weight gain
- ankylosing spondylitis
- primary care
- cardiovascular disease
- interstitial lung disease
- adipose tissue
- systemic lupus erythematosus
- risk assessment
- quality improvement
- systemic sclerosis
- climate change
- childhood cancer
- drug induced